Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 3: VC Firm Seeks Investment Opportunities in Digital Health and Medical Device Technologies that Address Problems of Large Unmet Need in Healthcare

28 Jun

A venture capital firm spun out of a leading university looks to provide primarily seed stage financings to companies ranging from $100K – $500k initially with up to $5-6 million provided over the lifetime of the investment. The firm prefers to invest in companies in the Eastern United States but is open to considering companies from around the globe. The firm could make as many as 6-7 investments over the next 6-9 months.

The firm is looking for companies working in sectors of digital health and more selectively medical devices. The firm is only interested in companies that are targeting very larger markets/unmet needs and is not interested in companies that require FDA Approval. The firm is especially interested in companies utilizing software for the optimization of various products and processes within healthcare. The firm is not interested in consumer-facing products.

The firm is very open to working with young entrepreneurs and generally looks to take a board seat following the investment. The firm is looking for companies with the potential to become very large organizations capable of being worth hundreds of millions of dollars.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , ,

Hot Investor Mandate 4: Investment Firm with Offices in USA, China, and India Invests Opportunistically in Life Sciences, with Strongest Interest in Novel Medical Devices and Cardiovascular Diseases

28 Jun

Founded in 2015, is a venture capital firm with offices in Boston, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 1: Japanese Pharmaceutical Seeks to Partner with Global Innovations in Therapeutics, Devices, Digital Health with Focus in Orthopedics, Respiratory, Cardivascular Diseases

21 Jun

A pharmaceutical company headquartered in Tokyo, Japan, focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The company has existing businesses in respiratory diseases, cardiovascular diseases, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The company is also interested in home patient monitoring products. In addition, the company is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the company is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the company had previously focused on late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases, but has expanded interests to consider early-stage opportunities. The company is most interested in small molecule and peptide drugs.

The company is looking for assets that are a compliment to its portfolio. The company prefers to own rights in the Japan market, while its partners can keep US or EU rights. The company’s regulatory team, clinical team and support system can assist its partners with product registration and distribution in Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , ,

Hot Investor Mandate 2: Subsidiary of Large Pharmaceutical Looking for Innovative Therapeutic Companies Developing Treatments for Rare Blood Diseases

21 Jun

A fully owned subsidiary of a large pharmaceutical that focuses on treating rare blood diseases. The company partners with and invests in early stage companies in the blood disease field using a variety of structures. The company is open to partnering with companies worldwide.

The company is focused solely on rare blood diseases, including hemophilia, sickle cell disease, cold agglutinin disease, and beta thalassemia; the firm will consider assets in any rare blood disease, but does not consider blood cancers or blood-born pathogens. The company will consider assets from the very early idea stage through to commercial products. In addition to any therapeutic drugs that treat blood diseases, the company is also interested in other modalities such as medical devices, wearables and digital technologies that help treat or manage blood diseases.

The company is open to working with companies and researchers from a very early stage; for companies that do not yet have a complete management team, the company may take an active role in building a team or guiding development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: ,

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

21 Jun

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

Hot Investor Mandate 4: Corporate Venture Arm of Global Pharma Seeks Therapeutics Companies with Focus on Pre-IND Assets in All Indications

21 Jun

A financially driven corporate life science venture fund of a global pharmaceutical company, invests with the purpose of fostering innovation, driving significant patient benefit, and generating superior returns by creating and investing in innovative life science companies at various stages of their development, independent from the corporate’s strategy. The firm has offices in USA and Europe, and focuses its investment activities in these countries. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , ,

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

14 Jun

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →